Victor Cheng, MD
Cardiovascular Disease · Minneapolis, MNNPI 1083744403
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $5,910 of the $7,288 with a category attached, or 81.1%. 7 manufacturers reported payments, led by Cleerly, Inc. at 54.5% of the total. 2025 is the largest year on record at $3,773, 9.7 times the $389 reported in 2019.
Across 17 payments — averaging $428.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cleerly, Inc.$4K
- Siemens Medical Solutions USA, Inc.$3K
- Heartflow, Inc.$179
- Globus Medical$123
- Canon Medical Informatics, Inc.$116
- Edwards Lifesciences$20
- plus $17 from 1 others
Across 13 payments — averaging $5399.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Edwards Lifesciences$70K
What the payments were for
- Speaking & faculty fees$5,91081%
- Food & beverage$1,37819%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cleerly, Inc. | 5 | $3,968 |
| Siemens Medical Solutions USA, Inc. | 6 | $2,864 |
| Heartflow, Inc. | 2 | $179 |
| Globus Medical | 1 | $123 |
| Canon Medical Informatics, Inc. | 1 | $116 |
| Edwards Lifesciences | 1 | $20 |
| Abbott | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Cleerly Ischemia$332
- Cleerly Labs$332
- NAEOTOM Alpha$255
- FFRct$162
- SOMATOM Force$133
- Pulse$123
- ADVANCED VISUALIZATION$116
How this compares
$7,288 in reported general payments places this provider in the 70th percentile of 451 cardiovascular disease providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 129 | $155,759 |
| Repatha SureclickEvolocumab | 80 | $83,575 |
| EntrestoSacubitril/Valsartan | 26 | $45,570 |
| XareltoRivaroxaban | 34 | $39,854 |
| Metoprolol Succinate | 222 | $4,506 |
| Rosuvastatin Calcium | 135 | $2,384 |
| Valsartan | 64 | $2,272 |
| Torsemide | 37 | $1,609 |
| Irbesartan | 46 | $1,454 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 35 | $1,306 |
| Atorvastatin Calcium | 60 | $1,063 |
| Amlodipine Besylate | 78 | $940 |
| Amiodarone Hcl | 13 | $806 |
| Metoprolol Tartrate | 69 | $720 |
| Potassium Chloride | 15 | $679 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Minneapolis
- Jeffrey ChambersMinneapolis$3.2M
- Markus MeyerMinneapolis$786K
- Robert SchwartzMinneapolis$502K
- Robert VantasselMinneapolis$493K
- Nedaa SkeikMinneapolis$453K
- Joao CavalcanteMinneapolis$384K
- Inderjit AnandMinneapolis$384K
- David HurrellMinneapolis$205K
- Yader Sandoval PichardoMinneapolis$157K
- Charles HerzogMinneapolis$157K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.